A list of changes in the level of risk of products reviewed in e-lactancia during the last 3 months is shown. Tap the name of a product to access to its full information.

Ginkgo. Ginkgo biloba

Level of risk reviewed on 01/07/2022

Increased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment., is now set to Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Periciazine; Pericyazine

Level of risk reviewed on 23/06/2022

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment., is now set to Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Ocrelizumab

Level of risk reviewed on 26/05/2022

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment., is now set to Safe. Compatible. Minimal risk for breastfeeding and infant.